ZnA Oncology fights oncology with a differentiated approach that combines stable isotope metallomics with a focus on proteome and immune responses.
Now Recruiting First Cohort of Patients In Phase 1 Clinical Trial
ZnA Oncology and our parent, Vector Vitale LLC, commences Phase 1 clinical trial of KLS-1 in adult human patients with malignant neoplasms. Check ZnA Bio pipeline. Visit ClinicalTrials.gov for more information.
July 2024
Phase 1/2 Clinical Trials Registered with ClincialTrials.gov
ZnA Oncology and our parent, Vector Vitale LLC, registers our Phase 1/2 clinical trials of KLS-1 in cancer patients with malignant neoplasms at ClinicalTrials.gov - a web-based resource and database that provides public access to information on clinical studies conducted around the world. Access ClinicalTrials.gov for more information.
July 26, 2024
Regulatory Approval Granted for Phase 1/2 Clinical Trial of KLS-1
The Ukraine's Ministry of Health (equivalent of U.S. FDA) has granted approval for our investigational new drug application, permitting us to conduct Phase 1/2 clinical trial of KLS-1 in cancer patients with malignant neoplasms. These clinical trials will be conducted by a certified clinical research organization, CLS Ukraine Ltd. at Arensia clinical research sites in accordance with U.S. FDA requirements.
May 28, 2024
An Investigational New Drug Application Submitted for KLS-1
Vector Vitale and ZnA Oncology submits for regulatory approval to the Ukraine's Ministry of Health, asking for the permission to conduct phase 1/2 human clinical trial. The review process usually takes up to 5 months and entails answering few round of comments.
March 10, 2024
Vector Vitale LLC Spins-Off Its Cancer Research With ZnA Oncology
Our parent, Vector Vitale LLC, the original developer of isotope-selective modulation (ISM) therapies, has commenced the spin-off of its 10-year oncology research into separate existence by creating our company. We are excited and honored to carry on the ISM research forward and to transform the lives of patients by mastering the discovery and development of effective and inherently safe immunotherapies of new generation.
March 5, 2024